<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 24 Sep 2025 08:34:25 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Survey shows 1/3 of GLP-1 users are lower-income</title>
   <link>http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</link>
   <description>&lt;p&gt;Investing.com -- A new BTIG survey of more than 1,000 GLP-1 users in the United States found that roughly one-third fall into the lower-income bracket, defined as earning less than $45,000 per year.&lt;/p&gt;&lt;p&gt;The brokerage analysts noted they were surprised by the findings given the high cost of these medications, which typically run $500 to $1,000 per month.&lt;/p&gt;&lt;p&gt;They said access has widened through compound scripts offered by companies like LifeMD and Hims and Hers for as little as $130, and in part through Medicaid coverage in several states.&lt;/p&gt;&lt;p&gt;Upper-income consumers, earning more than $75,000 annually, made up 44% of survey participants, while</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Survey+shows+13+of+GLP-1+users+are+lower-income/25369169.html</guid>
   <pubDate>Wed, 24 Sep 2025 08:34:25 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CMG</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HIMS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SG</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
  <item>
   <title>Argus cuts Wendy’s to Hold as U.S. sales weaken, outlook lowered</title>
   <link>http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</link>
   <description>&lt;p&gt;Investing.com --Argus downgraded Wendy’s to Hold from Buy, citing soft U.S. sales and traffic that are weighing on results despite gains overseas.&lt;/p&gt;
&lt;p&gt;The fast-food chain reported second-quarter revenue down 2% from a year earlier, with global sales slipping 1.8%. U.S. sales fell 3% and same-store sales dropped 3.6%, offset only partly by a 9% increase in international sales. &lt;br /&gt;&lt;br /&gt;Argus said international momentum is not enough to make up for the U.S. declines.&lt;/p&gt;
&lt;p&gt;Management lowered its 2025 guidance for the second quarter in a row. It now expects adjusted EPS of 82 to 89 cents, down from its prior range of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/General+News/Argus+cuts+Wendy%E2%80%99s+to+Hold+as+U.S.+sales+weaken%2C+outlook+lowered/25365233.html</guid>
   <pubDate>Tue, 23 Sep 2025 12:04:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MCDS</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TQK</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WEN</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">YUM</category>
   	  </item>
 </channel>
</rss>
